MedTrace Logo

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

NCT02619760 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3045

Last updated 2024-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).

Conditions

Interventions

DRUG

1-month DAPT

1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists

DRUG

12-month DAPT

12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists

Sponsors & Collaborators

  • Kyoto University, Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-08
Completion
2023-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619760 on ClinicalTrials.gov